-
Cy7 NHS Ester: Practical Labeling and QC
2026-09-16
Cy7 NHS ester (SKU A8109) is a water-soluble Sulfo-Cy7 NHS Ester for labeling accessible primary amines on proteins, peptides, and related biomolecules for near-infrared fluorescent imaging. It is well suited to aqueous workflows involving sensitive biomolecules, but it should not be selected for targets lacking accessible amino groups or for long-term storage of prepared dye solutions.
-
Clozapine N-oxide (CNO) in Reliable Cell Assays
2026-09-16
This scenario-based guide explains how Clozapine N-oxide (CNO), SKU A3317, can be integrated into DREADD-enabled viability, proliferation, and cytotoxicity workflows. It covers controls, solvent compatibility, stock handling, interpretation, and practical criteria for selecting a reliable research-grade source.
-
MLKL Polymerization Drives Lysosomal Permeabilization
2026-09-15
The reference study identifies lysosomal membrane permeabilization as a key execution step linking MLKL polymerization to necroptotic cell death. Using live-cell imaging, lysosomal leakage assays, and cathepsin B perturbation, it shows that MLKL-dependent lysosomal damage precedes plasma membrane rupture and promotes proteolytic destruction of survival factors.
-
Aurora A Overexpression in Retinoblastoma
2026-09-15
The 2024 American Journal of Pathology study identifies AURKA overexpression as a recurrent feature of human retinoblastoma and links it to histopathologic factors associated with high-risk disease. By combining patient specimens, genetic depletion, pharmacologic inhibition, xenografts, and patient-derived material, the work supports AURKA as a biologically relevant therapeutic target while also defining important limits for translation.
-
Recombinant Human EGF in Cancer Assays
2026-09-14
Explore how Epidermal Growth Factor and recombinant human EGF can be used as controlled assay variables in proliferation, apoptosis, and MYC-driven cancer research. This article connects EGF receptor biology with the EphA2 synthetic-lethality study while emphasizing experimental controls, product quality, and interpretation limits.
-
Angiotensin I/II (1-5): RAS Workflow Guide
2026-09-14
This guide explains how to prepare, handle, and quality-check Angiotensin I/II (1-5), an Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research. It is appropriate for cardiovascular, renal, blood pressure, and aldosterone-focused workflows, but should not be generalized to unrelated signaling studies without independent validation.
-
3-Deazaadenosine in Methylation Assays
2026-09-13
3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor for experimentally perturbing SAM-dependent methylation. This article explains how to use it alongside METTL14-centered assays to separate global methylation effects from locus-specific epitranscriptomic mechanisms.
-
FPS-ZM1: RAGE Signaling Beyond Alzheimer’s
2026-09-12
FPS-ZM1 is a selective RAGE inhibitor for separating receptor-dependent amyloid beta signaling from broader metabolic and inflammatory effects. This article converts recent RAGE/POMC findings into a causality-focused assay strategy for Alzheimer’s disease research and neuroinflammation studies.
-
MLKL Polymerization and Lysosomal Permeabilization
2026-09-11
The reference study identifies lysosomal membrane permeabilization as a key execution step in MLKL-driven necroptosis. Using live-cell imaging, MLKL-domain experiments, and cathepsin B perturbation, the authors connect MLKL polymerization to lysosomal disruption, cytosolic protease release, and cell death.
-
Iron Stress Reprograms Enterocyte Metabolism
2026-09-11
Navazesh and Ji used paired iron-deficiency and iron-excess perturbations in IPEC-J2 enterocytes to show that iron availability reshapes transcription, inflammation, proliferation, and intermediary metabolism. The study’s repletion experiment further indicates that some iron-stress metabolic changes are reversible, providing a useful framework for intestinal nutrition and barrier-function research.
-
DNA Removal as a Translational Control Point
2026-09-10
Clean nucleic-acid workflows are not merely technical housekeeping: they shape how confidently researchers interpret organoid, co-culture, RT-PCR, and transcription data. This thought-leadership article connects DNase I mechanism with the patient-specific pancreatic cancer organoid–fibroblast study by Schuth et al., then provides a strategic framework for deploying ribonuclease-free DNase I in translational workflows.
-
Amyloid Beta-Peptide (1-40): Mechanism to Translation
2026-09-10
A mechanistic and translational framework for using Amyloid Beta-Peptide (1-40) (human) to study membrane interactions, calcium-dependent aggregation, fibril formation, and neurotoxicity in Alzheimer’s disease research.
-
Sumatriptan Metabolism: CYP and MAO Revisited
2026-09-09
The reference study revisits the established view that sumatriptan is metabolized mainly through monoamine oxidase A and demonstrates additional, sequential N-demethylation by selected cytochrome P450 enzymes. Its recombinant-enzyme and HPLC-MS strategy clarifies how parallel CYP and MAO routes may shape metabolite profiles and provides a useful framework for interpreting drug metabolism in mechanistic research.
-
Nigericin Workflows for pH and Ion Transport
2026-09-09
Nigericin enables controlled potassium/proton exchange for intracellular pH modulation, mitochondrial stress studies, and mechanism-focused cancer assays. This workflow-led guide connects ion transport with metabolic readouts while separating practical assay recommendations from evidence generated in bacterial antibiotic research.
-
Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro
2026-09-08
The reference study used biochemical high-throughput screening, kinetic analysis, binding measurements, and molecular docking to identify merbromin as a selective mixed-type inhibitor of SARS-CoV-2 3CLpro. Its selectivity over Proteinase K, trypsin, and papain supports 3CLpro as a tractable antiviral target while also illustrating why broad-spectrum proteases are useful controls in inhibitor characterization.